Intercurrent events and comorbid conditions influence hemoglobin level variability in dialysis patients

Clinical Nephrology

Volumn 71, Issue 4, 2009, Pages 397-404

  DeFrancisco, A L M ^a   Macdougall, I C ^b   Carrera, F ^c   Braun, J ^d   Barany P ^e   Bridges, I ^f   Wheeler, T ^f   Tran, D ^f   Dietrich, A ^g  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c Eurodial   (Portugal)

^d KfH Kuratorium für Dialyse and Nierentransplantation E V   (Germany)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f AMGEN LTD   (United Kingdom)

^g AMGEN INC   (United States)

Author keywords

Dialysis; Erythropoiesis stimulating agents; Hemoglobin variability; Intercurrent events; Patient characteristics

Indexed keywords

IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGE; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; SEX DIFFERENCE; TRANSFERRIN BLOOD LEVEL;

EID: 66649114822     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP71397     Document Type: Article

References (26)

1. Barany P. Inflammation, serum C-reactive protein, and erythropoietin resistance. Nephrol Dial Transplant. 2001; 16: 224-227.
2. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB. Hemoglobin variability in epoietin-treated hemodialysis patients. Kidney Int. 2003; 64: 1514-1521.
3. Brunelli SM, Joffe MM, Israni RK, Yang W, Fishbane S, Berns JS, Feldman HI. History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin J Am Soc Nephrol. 2008; published online March 12, 2008.
4. Burnier M, Canaud B, De Francisco ALM, Braun J, Robbins S, Bridges I, Graebe A. Hemoglobin (Hb) variability: how should it be calculated and presented? A comparison of inter- versus intra-patient (Pt) variability (Abstract SU-PO820). Abstract and poster presented at the Annual Meeting of the American Society of Nephrology, October 31 to November 5. San Francisco: CA, USA; 2007.
5. Canaud B, De Francisco ALM, Braun J, Burnier M, Bridges I, Robbins S, Graebe A. Intercurrent events and comorbidities related to intra-patient hemoglobin variability (Abstract SA-PO782). Abstract and poster presented at the Annual Meeting of the American Society of Nephrology, October 31 to November 5. San Francisco: CA, USA; 2007.
6. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355: 2071-2084.
7. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol. 2006; 1: 1205-1210.
8. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined Phase I and II clinical trial. N Engl J Med. 1987; 316: 73-78.
9. Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol. 2007; 2: 1274-1282.
10. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Am J Kidney Dis. 1996; 28: 53-61.
11. Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol. 2008; 3: 133-138.
12. Ifudu O, Uribarri J, Rajwani I, Vlacich V, Reydel K, Delosreyes G, Friedman EA. Low hematocrit may connote a malnutrition/inflammation syndrome in hemodialysis patients. Dial Transplant. 2002; 31: 845-878.
13. Ishani A, Solid CA, Weinhandl ED, Gilbertson DT, Foley RN, Collins AJ. Association between number of months below K/DOQI hemoglobin target and risk of hospitalization and death. Nephrol Dial Transplant. 2007. (published online December 8, 2007).
14. Lacson E Jr, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis. 2003; 41: 111-124.
15. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU et al. Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant. 2004a; 19 (Suppl. 2): ii1-ii47.
16. Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L et al. Anaemia in hemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004b; 19: 121-132.
17. Mann J, Kessler M, Villa G, Martinez Castelao A, Feldt Rasmussen B, Cruz J, Hörl WH, Mattin C, Praml C, Wilkie M. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: c combined analysis of eight multicenter trials. Clin Nephrol. 2007; 67: 140-148.
18. National Kidney Foundation. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007; 50: 471-530.
19. Nurko S, Spirko R, Law A, Dennis VW. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoietin-α or darbepoie - tin-α: a retrospective cohort study. Clin Ther. 2007; 29: 2010-2021.
20. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int. 2003; 63: 1908-1914.
21. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target hemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a metaanalysis. Lancet. 2007; 369: 381-388.
22. Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004; 44: 94-111.
23. Rottembourg J, Kpade F, Tebibel F, Dansaert A, Chenuc G. Stable hemoglobin (Hb) in hemodialysis (HD) patients: Forest for the trees - a 12-week pilot observational observational study. Abstract and poster presented at the Annual Meeting of the American Society of Nephrology, October 31 to November 5, San Francisco: CA, USA; 2007.
24. Singh AK, Milford E, Fishbane S, Keithi-Reddy SR. Managing anemia in dialysis patients: Hemoglobin cycling and overshoot. Kidney Int. 2008 (published online March 12, 2008).
25. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoietin-α in chronic kidney disease. N Engl J Med. 2006; 355: 2085-2098.
26. Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol. 2007; 18: 3164-3170.